ALXN Upgraded To Conviction Buy At Goldman
Analysts at Goldman Sachs upgrade Alexion Pharma (NASDAQ: ALXN) from "buy" to "conviction buy." The target price for ALXN has been raised from $57 to $62.
ALXN’s shares closed at $52.85 yesterday. More Analyst Ratings here


























